BMS：SOTYKTU™Deucravacitinibapproved for marketing in China.
Daiichi Sankyo：Vanflyta®Quizartinib marketing application submitted
TUL：UBT251 has initiated a Phase III clinical trial.
MSD:WELIREG®Belzutifan was approved for marketing in the United States.
Tasly：TCM0012 approved for marketing in China.
Qilu：QLS2311 was approved
Biohaven：BHV-1400 initiates its first global Phase III trial.
Wockhardt：Zaynich ™ (Zidebactam and Cefepime)was approved
Shionogi：XOCOVA® (ensitrelvir)was approved for marketing in the United States.
J&J：Complete data for Nipocalimab were announced.
